HIRAK S. BASU

TitleAssociate Professor
InstitutionMD Anderson
DepartmentGenitourinary Medical Oncology
Address1515 Holcombe Blvd
Houston TX 77030-4009
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Basu HS, Wilganowski N, Robertson S, Reuben JM, Cohen EN, Zurita A, Ramachandran S, Xiao LC, Titus M, Wilding G. Prostate cancer cells survive anti-androgen and mitochondrial metabolic inhibitors by modulating glycolysis and mitochondrial metabolic activities. Prostate. 2021 09; 81(12):799-811. PMID: 34170017.
      Citations:    Fields:    Translation:HumansCells
    2. Mehraein-Ghomi F, Church DR, Schreiber CL, Weichmann AM, Basu HS, Wilding G. Inhibitor of p52 NF-?B subunit and androgen receptor (AR) interaction reduces growth of human prostate cancer cells by abrogating nuclear translocation of p52 and phosphorylated AR(ser81). Genes Cancer. 2015 Sep; 6(9-10):428-44. PMID: 26622945.
      Citations: 3     
    3. Huang SX, Yun BS, Ma M, Basu HS, Church DR, Ingenhorst G, Huang Y, Yang D, Lohman JR, Tang GL, Ju J, Liu T, Wilding G, Shen B. Leinamycin E1 acting as an anticancer prodrug activated by reactive oxygen species. Proc Natl Acad Sci U S A. 2015 Jul 07; 112(27):8278-83. PMID: 26056295.
      Citations: 15     Fields:    Translation:HumansCells
    4. Huang W, Eickhoff JC, Mehraein-Ghomi F, Church DR, Wilding G, Basu HS. Expression of spermidine/spermine N(1) -acetyl transferase (SSAT) in human prostate tissues is related to prostate cancer progression and metastasis. Prostate. 2015 Aug 01; 75(11):1150-9. PMID: 25893668.
      Citations: 20     Fields:    Translation:Humans
    5. Mehraein-Ghomi F, Kegel SJ, Church DR, Schmidt JS, Reuter QR, Saphner EL, Basu HS, Wilding G. Targeting androgen receptor and JunD interaction for prevention of prostate cancer progression. Prostate. 2014 May; 74(7):792-803. PMID: 24647988.
      Citations: 4     Fields:    Translation:HumansCells
    6. Basu HS, Mahlum A, Mehraein-Ghomi F, Kegel SJ, Guo S, Peters NR, Wilding G. Pretreatment with anti-oxidants sensitizes oxidatively stressed human cancer cells to growth inhibitory effect of suberoylanilide hydroxamic acid (SAHA). Cancer Chemother Pharmacol. 2011 Mar; 67(3):705-15. PMID: 20512578.
      Citations: 9     Fields:    Translation:HumansCells
    7. Mehraein-Ghomi F, Basu HS, Church DR, Hoffmann FM, Wilding G. Androgen receptor requires JunD as a coactivator to switch on an oxidative stress generation pathway in prostate cancer cells. Cancer Res. 2010 Jun 01; 70(11):4560-8. PMID: 20460526.
      Citations: 17     Fields:    Translation:HumansCells
    8. Basu HS, Thompson TA, Church DR, Clower CC, Mehraein-Ghomi F, Amlong CA, Martin CT, Woster PM, Lindstrom MJ, Wilding G. A small molecule polyamine oxidase inhibitor blocks androgen-induced oxidative stress and delays prostate cancer progression in the transgenic adenocarcinoma of the mouse prostate model. Cancer Res. 2009 Oct 01; 69(19):7689-95. PMID: 19773450.
      Citations: 22     Fields:    Translation:HumansAnimalsCells
    9. Mehraein-Ghomi F, Lee E, Church DR, Thompson TA, Basu HS, Wilding G. JunD mediates androgen-induced oxidative stress in androgen dependent LNCaP human prostate cancer cells. Prostate. 2008 Jun 15; 68(9):924-34. PMID: 18386285.
      Citations: 21     Fields:    Translation:HumansCells
    10. Church DR, Lee E, Thompson TA, Basu HS, Ripple MO, Ariazi EA, Wilding G. Induction of AP-1 activity by androgen activation of the androgen receptor in LNCaP human prostate carcinoma cells. Prostate. 2005 May 01; 63(2):155-68. PMID: 15486991.
      Citations: 12     Fields:    Translation:HumansCells
    11. Frydman B, Blokhin AV, Brummel S, Wilding G, Maxuitenko Y, Sarkar A, Bhattacharya S, Church D, Reddy VK, Kink JA, Marton LJ, Valasinas A, Basu HS. Cyclopropane-containing polyamine analogues are efficient growth inhibitors of a human prostate tumor xenograft in nude mice. J Med Chem. 2003 Oct 09; 46(21):4586-600. PMID: 14521420.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    12. Cytotoxicity of polyamine analogs is directly related to their DNA affinity as determined by polyacrylamide gel coelectrophoresis (PACE) method. Journal of Biological Systems. 12:387-397.
    13. Inhibitor of p52 NF-κB subunit and androgen receptor (AR) interaction reduces growth of human prostate cancer cells by abrogating nuclear translocation of p52 and phosphorylated ARser81 . Genes and Cancer. 6:428-444.
    14. Erratum. Cancer Research. 53:5063.
    15. Prostate-specific antigen. Expert Opinion on Therapeutic Patents. 12:1035-1046.
    BASU's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (104)
    Explore
    _
    Co-Authors (2)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _